Previous 10 | Next 10 |
Glaukos (NYSE: GKOS) , a specialty healthcare company that concentrates on eye disorders, enjoyed a very healthy pop in its share price on Wednesday. This followed the company's latest clinical update. Investors traded the stock up by almost 19%. That update was about iDose TR, ...
Glaukos Corporation ( NYSE: GKOS ), a MedTech company focused on eye diseases, announced Wednesday that two pivotal Phase 3 trials for its eye implant iDose TR reached primary efficacy endpoints in patients with open-angle glaucoma (OAG) or ocular hypertension. iDose TR cont...
Phase 3 Pivotal Trials Met Pre-Specified Primary Efficacy Endpoints for Both Doses of iDose TR (Fast- and Slow-Release Models), Supporting Anticipated Upcoming NDA Submission 93% of Slow-Release iDose TR Subjects Remained Well-Controlled on the Same or Fewer IOP-Lowering Topic...
MIGS Corporate Pioneer Achieves Unprecedented, Market-Leading Milestone Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today annou...
Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation PR Newswire BOSTON ...
IVeena Delivery Systems is granting Glaukos ( NYSE: GKOS ) an exclusive global license to develop and commercialize keratoconus therapy IVMED-80 eye drop. Under the agreement, Glaukos paid $10M upfront and will take up all costs linked with development and regulat...
Glaukos Corporation recognized a mixed quarter with upsides in revenue versus consensus. Revenue did however tighten year-on-year alongside gross margin by ~200bps. The downtrend carried down the P&L, although on examination, has been in situ for a number of periods. We ra...
Glaukos Corporation (GKOS) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Parti...
Glaukos press release ( NYSE: GKOS ): Q2 Non-GAAP EPS of -$0.83 misses by $0.39 . Revenue of $72.69M (-6.9% Y/Y) beats by $4.7M . The company expects 2022 net sales to be in the range of $275 million to $280 million from prior guidance of $270M-$275M vs. $...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highlights in...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...